立方制药(003020.SZ)：洛索洛芬钠口服溶液取得药品注册证书

Core Viewpoint - Cubic Pharmaceutical (003020.SZ) announced that its wholly-owned subsidiary, Hefei Chengzhi Biopharmaceutical Co., Ltd., received the drug registration certificate for Loxoprofen Sodium Oral Solution from the National Medical Products Administration, marking a significant milestone for the company in the pharmaceutical market [1] Company Summary - The approved product, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) with strong analgesic, anti-inflammatory, and antipyretic effects, particularly noted for its analgesic properties [1] - The indications for Loxoprofen Sodium include treatment for rheumatoid arthritis, osteoarthritis, low back pain, periarthritis of the shoulder, cervical spondylosis, dental pain, postoperative pain, trauma, and fever associated with acute upper respiratory infections [1] - The original developer of this drug is Japan's Nipro Corporation, and as of the announcement date, there are no imported products approved for sale in China, with only seven other domestic companies holding the drug's registration [1]